According to its website:
“California's
Stem Cell Agency was created in 2004 when 59% of California voters approved Proposition
71: the California Stem Cell Research and Cures Initiative. That initiative
created the California Institute for Regenerative Medicine (CIRM) to fund stem
cell research in the state. In addition to creating the agency, Prop 71 created
a 29-member governing
Board composed of researchers, business leaders and patient advocates.”
Somewhere along the way, CIRM had the good sense
to hire Kevin McCormack
as its Sr. Director of Public Communications and Patient Advocate
Outreach.
Fortunately, Kevin McCormack prepared a summary
of that workshop meeting. Here it is:
The meeting began with the hope that it would
produce a strong, robust discussion of the issues surrounding the use of CRISPR
to edit human embryos and to result in a series of recommendations that the
Standards Working Group (SWG) could then forward to the CIRM Board on whether
any changes needed to be made to our existing rules and regulations about
funding such research.
It turned out to be a thoroughly fascinating day
with some thought-provoking presentations and equally thought provoking
questions from the audience, from scientists, social researchers and members of
the public.
It quickly became clear that the discussion was
going to be even more robust than we imagined and the issues raised were too
many and too complex for us to hope reaching any conclusions or producing any
recommendations in one day.
In the end it was decided that the most
productive use of the day was not to limit the discussion at the workshop but
to get those present to highlight the issues and questions that were most
important and leave it to the SWG to then work through those and develop a
series of recommendations that would eventually be presented to the Board.
The questions to be answered included but are
not limited to:
1) Do we need
to reconsider the language used in getting informed consent from donors in
light of the ability of CRISPR and other technologies to do things that we
previously couldn’t easily do.
2) Can we use
CRISPR on previously donated materials/samples where general consent was given
without knowing that these technologies could be available or can we only
use it on biomaterials to be collected going forward.
3) Clarify
whether the language we use about genetic modification should also include mitochondrial
DNA as well as nuclear DNA.
4) The
possibility that somatic cell gene editing may lead to inadvertent germ line
editing
5) How do
we engage with patient advocates and other community groups such as the
social justice and equity movements to get their input on these topics –
do we need to do more outreach and education among the public or specific
groups and try to get more input from them (after all we are a taxpayer created
and funded organization so we clearly have some responsibility to the wider
California community and not just to researchers and patients)
6) As CIRM already
funds human embryo research should we consider funding the use of CRISPR and
other technologies that can modify the human embryo provided those embryos are
not going to be implanted in a human uterus.
This was a really detailed
dive into a subject that is clearly getting a lot of scientific attention
around the world and is no longer an abstract idea but is rapidly becoming a
scientific reality. The next step is for a subgroup of the SWG to put together
the key issues at stake here and place them in a framework for another
discussion with the full SWG at some point in the future.
Once the SWG has reached
consensus their recommendations will then go to the CIRM Board for its
consideration.
I hope this captures the
flavor and essence of what happened today. It really was a fascinating
discussion and the issues raised, and their complexity, highlighted why so many
different groups around the world are wrestling with the potential, and
pitfalls, of this new technology.
No comments:
Post a Comment